# Safety and Efficacy of Eltrombopag at Escalated Doses

> **NCT01880047** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 35 (actual)

## Conditions studied

- Immune Thrombocytopenia
- Platelet Disorder

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01880047
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2017-02-15
- **Final completion:** 2017-10-16
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01880047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01880047, "Safety and Efficacy of Eltrombopag at Escalated Doses". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01880047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*